Organisation paid for research Program year 2025 Source: CMS Open Payments

Buynak Clinical Research PC

Neither a doctor nor a teaching hospital

Research payments

$677,690

87 payments

Through program year 2025, Buynak Clinical Research PC is reported as receiving $677,690 in research payments, across 87 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $4,887 1
2024 Research $20,667 1
2023 Research $2,750 1
2022 Research $24,614 1
2021 Research $35,729 10
2020 Research $229,281 30
2019 Research $359,762 43

Breakdown

Who paid Research payments · program years 2019–2025
  1. Kowa Research Institute, Inc. $203,951 31 payments
  2. Pfizer Inc. $136,273 14 payments
  3. Sanofi US Services Inc. $118,439 17 payments
  4. Eisai Inc. $95,932 8 payments
  5. Novartis Pharmaceuticals Corporation $78,663 6 payments
  6. Janssen Research & Development, LLC $40,188 8 payments
  7. Regeneron Pharmaceuticals, Inc. $4,244 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. K-877-302 $115,825 18 payments
  2. A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR??in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years $95,932 8 payments
  3. K-877-302 $88,126 13 payments
  4. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function $78,193 12 payments
  5. A Phase 3 Randomized Double Blind Placebo and Activecontrolled Multicenter Parallelgroup Study of the Analgesic Efficacy and Safety of Tanezumab in Adult Subjects With Chronic Low Back Pain $68,053 2 payments
  6. An Open-Label Extension Trial of the Phase III Lipid-Lowering Trials to Assess the Effect of Long Term Dosing of Inclisiran Given As Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C $53,109 4 payments
  7. A Randomized, Double-blind Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Subjects with Type 2 Diabetes Mellitus $40,188 8 payments
  8. A Phase 3 Randomized Doubleblind Activecontrolled Multicenter Study of the Longterm Safety and Efficacy of Subcutaneous Administration of Tanezumab in Subjects With Osteoarthritis of the Hip Or Knee $35,514 2 payments
  9. A Phase 3 Randomized Doubleblind Placebocontrolled 26Week Multicenter Study With A 78Week Extension to Evaluate the Efficacy and Safety of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Metformin Mo $31,211 9 payments
  10. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $25,554 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record